A study in Tamil Nadu, India, finds that scrub typhus is a common yet under-recognized cause of fever, affecting up to 10% of ...

Vericel's FDA-approved regenerative medicine products and robust pipeline signal strong growth potential, with zero debt and ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will present a corporate overview at ...

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness ...

Findings in Burns Journal confirm NexoBrid’s superiority over standard of care in pediatric patients with deep thermal ...

MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

A webcast of the presentations will be available on the Investor Relations section of the Vericel Corporation website at: https://investors.vcel.com.

These results reinforce NexoBrid’s clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, validating its significance as a ...

Typical lesions progress from red or gray macules or papules, to red or gray macules or papules with a central eschar or ulceration. This evolution is a consequence of the thrombosis of dermal ...